Endotoxin release from Escherichia coli after exposure to tobramycin: dose-dependency and reduction in cefuroxime-induced endotoxin release J. SjöUlin,

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Laboratory diagnosis and biosafety issues of biological warfare agents

K. Kümmerer, A. Henninger Clinical Microbiology and Infection

Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times F.B. Spencker, L. Staber, T. Lietz,

Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens.

Gut bacterial microbiota and obesity

Approach to diagnosis of infective endocarditis

Herpes zoster in non-hospitalized children

Migrant health—a cause for concern?

K. Kümmerer, A. Henninger Clinical Microbiology and Infection

Trends in quinolone susceptibility of Enterobacteriaceae among inpatients of a large university hospital: 1992–98 J. Robert, E. Cambau, K. Grenet, D.

Current patterns and evolution of antibiotic resistance among bacterial pathogens involved in acute otitis media Fernando Baquero, Rafael Cantón, Fernando.

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

Non-antibiotic strategies for sepsis

P. Davey, C. Pagliari, A. Hayes Clinical Microbiology and Infection

W. Witte, B. Pasemann, C. Cuny Clinical Microbiology and Infection

How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach D. Guillemot Clinical Microbiology.

Structure of grepafloxacin relative to activity and safety profile

Vector control: a cornerstone in the malaria elimination campaign

Pharmacodynamics of doxycycline

Inga Odenholt, Elisabeth Löwdin, Otto Cars

Fourth-generation cephalosporins: a review of in vitro activity, pharmacokinetics, pharmacodynamics and clinical utility Javier Garau, Walter Wilson,

C-3′Quaternary Ammonium Cephems, a New Wave of Cephalosporins

Training for the infectious diseases speciality in Norway

Laboratory diagnosis and biosafety issues of biological warfare agents

Comparative in vitro activity of ertapenem against bacterial pathogens isolated from patients with lower respiratory tract infections P.S. Hicks, B.

Comparative in vitro pharmacodynamics of BO-2727, meropenem and imipenem against Gram-positive and Gram-negative bacteria Inga Odenholt, Elisabeth Löwdin,

G. Kronvall Clinical Microbiology and Infection

Elements of design: the knowledge on which we build

In vitro selection of antibiotic resistance in Pseudomonas aeruginosa

Antimicrobial susceptibility in Escherichia coli of human and avian origin—a comparison of wild-type distributions M. Sjölund, S. Bengtsson, J. Bonnedahl,

Levofloxacin in the treatment of ventilator-associated pneumonia

Metagenomics and probiotics

Effect of antioxidants on the immune response of Helicobacter pylori

L. Vogel, E. van Oorschot, H.M.E. Maas, B. Minderhoud, L. Dijkshoorn

L. Arreaza, J.A. Vázquez Clinical Microbiology and Infection

Laboratory diagnosis of Clostridium difficile disease

W.A. Craig Clinical Microbiology and Infection

Recent developments in staphylococcal scalded skin syndrome

G.R. Davies Clinical Microbiology and Infection

Single- and multistep selection study of the antipneumococcal activity of BMS compared to ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin

Harmonised monitoring of antimicrobial resistance in Salmonella and Campylobacter isolates from food animals in the European Union S. Bronzwaer Clinical.

Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens.

Pandemic lineages of extraintestinal pathogenic Escherichia coli

Training in infectious diseases and tropical medicine in Britain

Lack of antimicrobial activity of sodium heparin for treating experimental catheter-related infection due to Staphylococcus aureus using the antibiotic-lock.

Clinical infection services—the Leiden experience

M.B. Kerrn, N. Frimodt-Møller, F. Espersen

Statin use and clinical outcomes among pneumonia patients

Clinical Microbiology and Infection

Clinical Microbiology and Infection

The influence of protein binding on the antibacterial activity of faropenem against Haemophilus influenzae I. Gustafsson, O. Cars Clinical Microbiology.

W. Eugene Sanders, Christine C. Sanders

Overview of cefixime use in community-acquired infections

The in vitro activity of moxifloxacin against Haemophilus influenzae and Moraxella catarrhalis explored using a pharmacodynamic model Alasdair P. MacGowan,

Facilitating learning and change in physicians: Implications for a system of continuing medical education in Europe Robert D. Fox Clinical Microbiology.

Abstracts Clinical Microbiology and Infection

New oral cephalosporins in pediatric community-acquired infections

Carratalà J. Clinical Microbiology and Infection

In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species† C.B. Moore,

O. Megged, A.M. Yinnon, D. Raveh, B. Rudensky, Y. Schlesinger

N. Markeas, G. Stamos, I. Paraskakis, A. Giokas, G. Pistevos

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

Typing of Clostridium difficile

Raffaele Del Prete, M. D. , Maria Raffaella Buongiorno, B. Sc

The first glycopeptide-intermediate Staphylococcus aureus in Oman

Impact of antibiotic restrictions: the patient's perspective

Abstracts Clinical Microbiology and Infection

The future of diagnostic bacteriology

Presentation transcript:

Endotoxin release from Escherichia coli after exposure to tobramycin: dose-dependency and reduction in cefuroxime-induced endotoxin release J. SjöUlin, G. Goscinski, M. Lundholm, J. Bring, I. Odenholt Clinical Microbiology and Infection Volume 6, Issue 2, Pages 74-81 (February 2000) DOI: 10.1046/j.1469-0691.2000.00025.x Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 1 Endotoxin release per killed bacterium 4h after exposure to antibiotics at 2 × MIC, 10 × MIC, and 50 × MIC. Clinical Microbiology and Infection 2000 6, 74-81DOI: (10.1046/j.1469-0691.2000.00025.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 2 Relationship between endotoxin release and bacterial killing rate for tobramycin and tobramycin+cefuroxime at 2 × MIC, 10 × MIC, and 50 × MIC, respectively. Clinical Microbiology and Infection 2000 6, 74-81DOI: (10.1046/j.1469-0691.2000.00025.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 3 Changes in endotoxin concentration after addition of 10, 50, and 100 × MIC (2.5, 12.5, and 25mg/L) of tobramycin to broth spiked with endotoxin at two different endotoxin levels. The shaded area represents the 95% confidence interval based on the triplicate measurements in the control allocated to the mean endotoxin concentration at time zero. Clinical Microbiology and Infection 2000 6, 74-81DOI: (10.1046/j.1469-0691.2000.00025.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 4 Reduction in 4h cefuroxime-induced endotoxin release after addition of tobramycin at 10, 50, and 100 × MIC at 2h, expressed as percentage of that caused by cefuroxime at 10 × MIC alone. For comparison, the result of the simultaneous exposure of tobramycin and cefuroxime at 10 × MIC, obtained from the data also shown in Figure 1, has been included. Clinical Microbiology and Infection 2000 6, 74-81DOI: (10.1046/j.1469-0691.2000.00025.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions